Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.438.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.27NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.30NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.188NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.39NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.357NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BP.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.46NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.3.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.530NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.17.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.75.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.570NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.633NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DD.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.136NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAYNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DJ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAENSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.467NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.484NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.476NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.404NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CV.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DJ.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.73NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DW.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BR.5.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAKNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.226NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.546NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.194NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.429.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.1.9 (Gamma)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.25.1.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.203NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.157NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.176NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.3.4 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.391NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.393NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.432NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.388NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.48NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.112NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used